Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to -$481000.0.

  • Upstream Bio's Change in Accured Expenses fell 28571.43% to -$481000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 64444.44%. This contributed to the annual value of $1.5 million for FY2024, which is 25829.38% up from last year.
  • Per Upstream Bio's latest filing, its Change in Accured Expenses stood at -$481000.0 for Q3 2025, which was down 28571.43% from $3.5 million recorded in Q2 2025.
  • In the past 5 years, Upstream Bio's Change in Accured Expenses ranged from a high of $3.5 million in Q2 2025 and a low of -$1.9 million during Q1 2025
  • Over the past 3 years, Upstream Bio's median Change in Accured Expenses value was $320500.0 (recorded in 2024), while the average stood at $418000.0.
  • The largest annual percentage gain for Upstream Bio's Change in Accured Expenses in the last 5 years was 82277.49% (2025), contrasted with its biggest fall of 28571.43% (2025).
  • Over the past 3 years, Upstream Bio's Change in Accured Expenses (Quarter) stood at $639000.0 in 2023, then surged by 174.65% to $1.8 million in 2024, then plummeted by 127.41% to -$481000.0 in 2025.
  • Its Change in Accured Expenses stands at -$481000.0 for Q3 2025, versus $3.5 million for Q2 2025 and -$1.9 million for Q1 2025.